Therapeutic Platform
Transforming Postoperative Care with Innovative Science

Driving the Future of Gut Health
At 32 Biosciences, we’ve developed a novel solution to tackle surgical site infections (SSIs) by understanding and leveraging the microbiome’s nutrient ecosystem.
The Problem
Dysbiosis plus phosphate shifts are risk factors for surgical site infection
During surgery, the gut’s phosphate levels—a critical nutrient for bacterial growth—are depleted. This nutrient scarcity triggers certain gut bacteria to activate virulence genes.
Patients with dysbiosis have a depleted gut mucous barrier and a greater number of potential pathogens which increases the risk of infection once virulence genes are activated.

The Problem: Dysbiosis plus phosphate shifts are risk factors for surgical site infection
- During surgery, the gut’s phosphate levels—a critical nutrient for bacterial growth—are depleted
- This nutrient scarcity triggers certain gut bacteria to activate virulence genes
- Patients with dysbiosis have a depleted gut mucous barrier and a greater number of potential pathogens which increases the risk of infection once virulence genes are activated

Our Solution: CS Therapeutic Platform Technology
Our CS Therapeutic Platform is a first-of-its-kind, non-antibiotic antimicrobial therapy that targets infections by providing a key nutrient to bacteria instead of killing them.

At the forefront of this innovation is CS-0003, a phosphorylated triblock copolymer designed to suppress bacterial virulence by mimicking high-phosphate environments and coating bacterial surfaces. Its amphiphilic structure, with a hydrophobic core and hydrophilic, phosphate-functionalized segments, suppress bacterial virulence gene expression through the PstS-PhoB pathway.
Proven effective in robust animal models, CS-0003 significantly reduces infection rates and infection-related mortality without contributing to antibiotic resistance, offering a transformative approach to infection prophylaxis.